S&P 500 Futures decline towards 3,600 amid mixed clues on covid vaccine
|- S&P 500 Futures drop for the third day after rising to three week high earlier in the week.
- UK Government pushes for AstraZeneca’s fast-track approval after news of an extra trial.
- Trump said the vaccine will be delivered starting next week.
- Virus/vaccine updates and trade/political tussles among key economies should be watched amid a light calendar.
S&P 500 Futures drops 0.30% to 3,617 amid the initial hour of Tokyo open on Friday. The risk barometer declines for the third consecutive day amid mixed signals over the coronavirus (COVID-19) vaccines. Also challenging the mood could be the fears of further escalation in the virus cases before the cure hit the floor.
The UK Government is pushing the Medicines and Healthcare Products Regulatory Agency (MHRA) to assess Oxford/AstraZeneca covid-19 vaccine for a temporary supply. The reason could be traced from the British drug manufacturer’s announcement on Thursday that they’re holding one more trial amid some production issues over the less-dosage vaccine.
On the positive side, US President Donald Trump said that the vaccine will be delivered from next week. It should be noted that the latest covid number from Texas and California have been worrisome.
Elsewhere, the US-China and the Washington-Tehran tensions have recently been challenging the optimists trying to cheer the vaccine hopes and the expectations of the US recovery backed by the new government team.
That said, the US 10-year Treasury yields drop 3.3 basis points (bps), to currently around 0.84%, whereas stocks in Asia-Pacific trade mixed.
Looking forward, a lack of major data/events can extend the previous day’s inactive mood, led by the US Thanksgiving Day. Though, fresh challenges to the risk can help the market trim earlier gains.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.